On July 26, 2018, Nabriva Therapeutics plc (NASDAQ:NBRVF), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share. In addition, Nabriva Therapeutics granted the underwriters an option for a period of 30 days to purchase up to an additional 2,727,272 ordinary shares at the public offering price, less the underwriting discounts and commissions.

Two days prior, Nabriva Therapeutics announced that it acquired Zavante Therapeutics, a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients, for upfront consideration of approximately 8.2 million of Nabriva Therapeutics' ordinary shares (which includes an indemnity holdback) to Zavante’s former stockholders upon completion of the acquisition. In addition, Zavante’s former stockholders are eligible to receive up to $97.5 million upon the achievement of specified regulatory and commercial milestones, which subject to approval by Nabriva Therapeutics' shareholders and specified limitations, may be settled in Nabriva Therapeutics' ordinary shares.

WilmerHale acted as legal advisor to Nabriva Therapeutics in these transactions, with Brian Johnson leading a team that included Joe Conahan, Jeffries Oliver-Li, Mark Nylen and Ryan Crane (M&A); Kimberly Wethly and Ciara Baker (executive compensation); Amy Null (benefits); Richard Andersen, Julie Hogan Rodgers and Meghan Walsh (tax); Colleen Superko (intellectual property); Bruce Manheim (FDA); Belinda Juran (technology transactions & licensing); Heidi Treiber (Nasdaq matters); and Sarah Sellers, Alicia Lee, Libby Ragan and Morgan Monroe (public offering and general corporate).